Human papillomavirus (9-valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase II for Human Papillomavirus Infections.

Inpegsomatropin is under clinical development by Xiamen Amoytop Biotech and currently in Phase II for Turner Syndrome.

Taiwan's Mainland Affairs Council is investigating claims from a video alleging China's political influence on young ...

Marriott International has announced the signing of an agreement with Xiamen Green Development to launch The Ritz-Carlton in ...

China’s Mainland Affairs Council (MAC) said they will investigate claims made in a YouTube video about China’s efforts to ...

Chinese conglomerate Xiamen C&D and Russia's Nornickel are in talks to create a joint venture in China to process Nornickel's ...

CATL said on Wednesday it had co-developed 10 new electric vehicle models with automakers that use swappable batteries, as ...

International announced the signing of an agreement with Xiamen Green Development Investment Group to introduce The ...

Marriott International, Inc. today announced the signing of an agreement with Xiamen Green Development Investment Group to ...

Xiamen Hithium Energy Storage Technology Co. is considering an initial public offering in Hong Kong as soon as next year, ...

The world’s largest maker of batteries for electric vehicles says it will get into battery swapping in China in a big way ...